Compare top Immunotherapy for prostate cancer doctors and prices in Turkey. Find your best match here.
We'll hand-pick the best doctors based on your needs and budget.
Meet the experts behind this page
Medically reviewed by Fahad Mawlood
Medical Editor & Data ScientistTop doctors
1
Turkey
Reviews
14,000+
From real patients
Compare prices for Immunotherapy for prostate cancer across top countries
Tap a country to view top doctors and prices
Get free personalized treatment plans and choose the best option. No commitment · No payments for our services
Dr. Alemdar specializes in medical oncology with a focus on prostate cancer immunotherapy at Medical Park Antalya Hospital Complex.
Choosing a clinic abroad can be stressful. At Bookimed, with over 800K patients helped, we understand your concerns. We know how to find trusted doctors, the best price-quality options, and solutions for even complex cases. We’re here to guide you every step of the way.
Yan Matsiivskiy
Head of Medical Coordinator Team
4300++ patient journeys guided
3 years at Bookimed
278 patients from Turkey have found their doctor through us this month
2 min Quiz
Tell us your goal, budget, timeline
Human Matching + AI
Our algorithm finds matches, coordinator verifies fit
Your Options Ready
Compare prices, packages, dates. Chat with your coordinator
Overwhelmed by choices?
Guiding your treatment
Medically trained personal coordinators
| Rank | Doctor | experience | Good Fit For | What Sets Them Apart | Clinic & Location | Consultation |
|---|---|---|---|---|---|---|
| #1 | 20 years of experience | Prostate cancer immunotherapy | Specializes in prostate cancer immunotherapy with training from Akdeniz University. Board-certified in medical oncology with extensive clinical experience. | Turkey | Price on request
|
Top immunotherapy doctors in Turkey are medical oncologists with academic titles like Professor or Associate Professor. They hold European Society for Medical Oncology (ESMO) certification and specialize in molecular tumor biology. These experts practice in JCI-accredited centers that collaborate with major international medical institutions.
Bookimed Expert Insight: Data shows that top-tier Turkish oncologists often integrate molecular diagnostics into personalized care. For instance, Dr. Cemil Bilir trained at the Cleveland Clinic in nanomedicine, while Dr. Yesim Yildirim has published 80+ papers. This research-heavy background is crucial for determining if a patient is eligible for specific immunotherapy drugs based on genetic markers.
Patient Consensus: Patients note it is important to choose doctors who explain why immunotherapy fits their specific cancer subtype. They often feel more confident with specialists who work in multidisciplinary teams alongside urologists. Many suggest asking how the doctor manages potential immune-related side effects during treatment.
Turkish medical oncologists provide access to advanced prostate cancer protocols using checkpoint inhibitors and targeted therapies. While CAR-T remains experimental for solid tumors, specialists at Anadolu Medical Center and Hisar Hospital integrate international expertise from MD Anderson and Johns Hopkins Medicine to manage complex cases.
Bookimed Expert Insight: Data shows that premier Turkish centers often serve as extension hubs for American standards. For example, Anadolu Medical Center's affiliation with Johns Hopkins Medicine allows doctors to provide molecular profiling. This ensures patients receive immunotherapy tracks aligned with US clinical protocols. Expert consultations are available starting from $100 with Dr. Mustafa Solak and $215 with specialists at Anadolu.
Patient Consensus: Patients note it is important to clarify the specific type of immunotherapy before traveling. Many say they had to distinguish between standard drug treatments and experimental clinical trials. Those who traveled emphasize that clear communication about cell therapy types helped manage their expectations.
Verifying a doctor's expertise in prostate cancer immunotherapy requires analyzing their academic research history and clinical certifications. In Turkey, top oncologists combine intensive clinical practice with roles in international trials. You should prioritize doctors with European Society for Medical Oncology certification and active records in peer-reviewed research.
Bookimed Expert Insight: For complex prostate cases, the most experienced doctors in Turkey often hold joint appointments as university professors. Dr. Yesim Yildirim and Dr. Bulent Karagoz both balance clinical work with academic leadership. This ensures they are using the latest immunotherapy protocols long before they become standard practice. Patients may also book consultations with these specialists starting from $215.
Patient Consensus: Patients note it's important to ask how many immunotherapy cases the doctor handled in the last year. They recommend checking if the surgeon participates in multidisciplinary boards rather than making solo treatment decisions. Many were surprised by the depth of detail doctors provided about specific biomarkers during the initial consultation.
Turkish oncologists provide personalised immunotherapy for prostate cancer using biomarker profiling and genetic sequencing. Specialists like Dr. Bulent Karagoz and Dr. Yesim Yildirim at Anadolu Medical Center design precision protocols. These treatments align with international standards set by the European Society for Medical Oncology (ESMO).
Bookimed Expert Insight: While immunotherapy is often linked to academic centers, Turkish experts bridge the gap between research and practice. Dr. Nail Paksoy and Dr. Cemil Bilir integrate nanomedicine and clinical trial data directly into patient care. This ensures that even rare biomarker-positive cases receive protocols often found only at major global research institutes.
Patient Consensus: Patients note that biomarker testing is the essential first step before starting any therapy. They emphasize the importance of confirming genetic markers like MSI-high to ensure a drug will work. Many felt more confident after having their genomic reports reviewed by a multidisciplinary oncology board.